dc.contributor.author | Schuster, Cornelia | |
dc.contributor.author | Akslen, Lars Andreas | |
dc.contributor.author | Straume, Oddbjørn | |
dc.date.accessioned | 2023-12-21T13:51:13Z | |
dc.date.available | 2023-12-21T13:51:13Z | |
dc.date.created | 2023-10-06T12:18:11Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2045-7634 | |
dc.identifier.uri | https://hdl.handle.net/11250/3108651 | |
dc.description.abstract | Background
Vascular endothelial growth factor (VEGF) was initially known as vascular permeability factor and identified as a driver of tumour angiogenesis. Recently, its role in supporting an immunosuppressive tumour microenvironment was demonstrated, and anti-VEGF treatment combined with immune checkpoint blockade is currently investigated. Further, beta-adrenergic signalling as a modifier of cancer hallmarks like immune response, angiogenesis and metastasis gained increased attention during past years.
Methods
Focusing on the aspect of immunosuppression in upregulated beta-adrenergic signalling, we investigated predictive markers in patients with metastatic melanoma who received bevacizumab monotherapy, a specific VEGF-A binding antibody. We explored the expression of beta-2 adrenergic receptor (β2-AR), interleukin 6-receptor (IL6-R), cyclooxygenase 2 (COX2) and VEGF-A by immunohistochemistry in melanoma to assess the correlation between these proteins in melanoma cells and response to treatment.
Results
Strong β2-AR expression in metastases was associated with clinical benefit of bevacizumab. Furthermore, expression of the latter was positively linked to expression of VEGF-A and COX2. β2-AR expression in melanoma metastasis appears to distinguish a subgroup of patients that might benefit from anti-VEGF treatment.
Conclusion
Our results strengthen further exploration of anti-VEGF therapy in combination with immune checkpoint blockade in clinical studies and the investigation of β2-AR as predictive marker. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1002/cam4.6424 | |
dc.identifier.cristin | 2182418 | |
dc.source.journal | Cancer Medicine | en_US |
dc.source.pagenumber | 17891-17900 | en_US |
dc.identifier.citation | Cancer Medicine. 2023, 12 (17), 17891-17900. | en_US |
dc.source.volume | 12 | en_US |
dc.source.issue | 17 | en_US |